Date:
Friday, 25 February 2022
Time:
HiFi sequencing allows researchers around world the ability to see more, and to do more. With highly accurate long-read sequencing, researchers can see beyond the ordinary in the pursuit of uncovering new discoveries in their scientific research.
In this webinar, Dr. Nina Gonzaludo will review how PacBio HiFi reads enable complete and unambiguous HLA resolution without fragmentation. Long HiFi reads fully span complete HLA class I genes, as well as long amplicons of class II genes, allowing for at least four-field HLA typing without imputation. We review studies that leveraged PacBio sequencing to fully capture this highly homologous and polymorphic region, allowing researchers to identify true HLA allelic diversity.
Additionally, our invited guest speaker; Dr. Masahito Kawazu of the Chiba Cancer Center Research Institute will talk about the sequencing of HLA-A, B, C genes in tumor samples using long-read technology. The use of long-reads for HLA sequencing of tumor samples has several advantages, such as complete sequencing of entire alleles. On the other hand, several technical points need to be considered to avoid false positives and false negatives. The importance of HLA mutation analysis in understanding anti-tumor immunity and the technical issues in the choice of HLA sequencing will be discussed.
Masahito Kawazu began his medical research after studying medicine at the University of Tokyo and being trained as a hematologist. After earning a degree in research on transcription factors and conducting research on transcriptional regulators as a postdoctoral fellow, he joined the Department of Cellular Signaling, The University of Tokyo, in 2010 and started his research on genomic medicine. His main research theme is to elucidate the pathogenesis of cancer, focusing on immunogenomic analysis using long read sequencers.
Nina Gonzaludo is the global lead for Pharmacogenomics and HLA, a space where she has very deep experience. Nina has a background in bioinformatics, data science, genomics and pharmacogenomics and she earned her PhD in Pharmaceutical Sciences and Pharmacogenomics at UCSF. For her thesis, she worked with Kaiser Permanente to combine genotyping and 20 years of electronic health record data to study the impact and cost-effectiveness of pre-emptive pharmacogenomics in a clinical population. Nina has worked for Roche in bioinformatics developing machine learning methods with microarray data. Most recently Nina was at Illumina working with various groups in Medical Genomics Research where she worked on health outcomes and cost effectiveness studies and publications for pediatric rare disease using real world data and led the clinical whole genome sequencing-based Pharmacogenomics product team.
Connect with one of our scientists today
Complete the form to
register for this webinar
Masahito Kawazu, Ph.D.
Division Head
Division of Cell Therapy
Chiba Cancer Center Research Institute
Nina Gonzaludo, Ph.D.
Sr. Manager
Pharmacogenomics & HLA Market Development
PacBio
